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Summary 
Recurrence of cytomegalovirus (CMV) from latency is a frequent cause of disease in immuno- 
compromised patients.  To date, there is no explanation for the diversity in the clinical manifestations. 
Primary infection can occur perinatally or later in life, and inevitably results in latent infection. 
Seropositivity for antibodies against  CMV is indicative of latent  infection, but is insufficient 
as a predictor for the risk of recurrence.  As a model for this important  medical problem,  we 
compared the risks of murine CMV recurrence from latency established after neonatal primary 
infection and after infection at adult age. The risk of CMV recurrence was high only after neonatal 
infection. The copy number of latent viral genome in tissues was identified as the key parameter 
that determines the overall and organ-specific risks of recurrence. Latent CMV burden and risk 
of recurrence were related to the extent of virus multiplication  during primary infection. The 
presence of latent  CMV in multiple organs provides the molecular basis for stochastic events 
of recurrence in single organs  or in any combination thereof.  These findings  are discussed as 
a concept of multifocal CMV latency and recurrence.  It provides a rationale  for the diversity 
in the clinical  outcome of CMV disease. 
H 
uman CMV, the human herpesvirus type 5 (HHV-5), 1 
is the prototype of the B-subfamily of the herpesviruses 
(1-3). In general, herpesvirus infections are effectively con- 
trolled by the immune system, but without the ultimate dear- 
ance of the virus. Instead, the viral genome is retained at specific 
sites in a latent state out of which reactivation to recurrent 
infection and recrudescent disease can occur (4, 5). Primary 
infection, as well as recurrence from latency, leads to overt 
manifestations of herpesvirus disease in immunologically im- 
mature  or  immunocompromised  individuals.  Specifically, 
HHV-5 infection is teratogenic during fetal development and 
is a major cause of birth defects, its disease  manifestations 
contribute to AIDS, and it is the major viral cause of post- 
transplantation  disease in bone marrow transplantation  and 
solid organ transplantation recipients (for a review see refer- 
ence 6). Disease can result from recurrence of endogenous 
HHV-5 in the transplant recipient.  In addition, various organs 
and  blood-borne  cells  from  seropositive  donors  transmit 
HHV-5 (for a review see reference 7). Manifestations of CMV 
disease are diverse and range from specific organ to multiorgan 
1 Abbreviations used in this paper: HHV-5, human herpesvirus type 5; IE, 
immediate early; MEF, mouse embryo fibroblast. 
diseases.  So far, there is no unifying concept that could ex- 
plain such diversity.  However, the target organ of HHV-5 
is often the transplanted organ itself. Thus, the incidence of 
CMV hepatitis was found to be increased in liver transplant 
recipients as was that of pneumonitis in lung and heart/lung 
transplant recipients (7). This suggests an identity between 
the site of recurrence and that of disease manifestation. Anti- 
bodies to CMV are indicative of latent infection and serve 
to define a qualitative risk (8). Ablation of cellular immune 
control is a prime risk factor for CMV recurrence, but it is 
apparent that not all risk patients develop CMV disease. The 
definition of further risk factors is therefore fundamental to 
any risk prediction. 
Murine models of CMV latency and recurrence serve to 
answer open questions that cannot easily be addressed in clinical 
research (for a review see reference 9). As with HHV-5, la- 
tent murine CMV, the murid herpesvirus 1 (1), can be trans- 
mitted by organ transplantation (10, 11), and we have shown 
in previous work (12) that latency in organs is not explained 
by latently infected, circulating,  or tissue-resident  blood-borne 
cells. The existence of multiple organ sites of CMV latency 
implies the possibility of independent  events of recurrence 
at these sites. 
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latency and recurrence.  Specifically, it is demonstrated  that 
the course of primary infection defines the overall load with 
latent CMV, and that the copy numbers of latent viral genome 
in organs correlate with  organ-specific risks  of recurrence. 
Materials and Methods 
Infection and Immunization of Mice.  Female BALB/c mice, bred 
and housed at  our facility (University of Ulm)  under specified 
pathogen-free conditions, were infected as outlined in the first sec- 
tion of Results with the Smith strain of murine CMV (ATCC VR- 
194; American Type Culture Collection, Rockville, MD) that was 
propagated in cell culture and sucrose-gradient purified (12). For 
testing  passive  immunization  with  immune  serum,  8-wk-old 
BALB/c mice were subcutaneously infected with 105 PFU of mu- 
rine CMV at the left hind footpad 3 h after a syngeneic bone marrow 
transplantation comprising total body 3,-irradiation  with a single 
dose of 6 Gy followed by i.v. infusion of 106 femoral bone marrow 
cells from uninfected donors. The passive immunization was per- 
formed by i.v. infusion of native serum the day before infection. 
To  serve  as  the  serum  donors,  C57B1/6  mice  (B6)  and  B 
cell-deficient, homozygous #MT/#MT mutants (13) backcrossed 
to B6 were actively immunized by two i.v. infusions of inactivated 
murine CMV (107 PFU inactivated by 254 nm UV light) within 
3 wk.  The serum was  tested 3 wk  after the boost. 
Induction and Assay of Recurrent Infection.  CMV recurrence was 
induced by total body y-irradiation of latently infected mice with 
a single dose of 6 Gy from a cesium-137  source delivering a dose 
rate of 0.708 Gy/min. For plus-minus scoring done 2 wk after the 
irradiation, recurrent virus was detected from organ homogenates 
by an in vitro plaque assay with centrifugal enhancement of infec- 
tivity on permissive  mouse embryo fibroblast (MEF) monolayers 
essentially as described previously (14), except that no methylcellu- 
lose overlay was  made and all of the homogenate of each organ 
was  plated to exploit the full sensitivity.  Primary plaques  were 
counted after 3-4 d, and negative results were affirmed by the ab- 
sence of plaques during 10 d of the assay culture. A negative score 
was given if no plaque was detected after 10 d. For the determina- 
tion of virus titers, the plaque assay was performed with methyl- 
cellulose to preclude secondary plaque formation, and usually 1% 
of each organ homogenate was then plated, which defines the de- 
tection limit of this assay as 100 PFU per organ. It is an inherent 
problem of virus quantification in organs of seropositive mice that 
neutralizing antibody contained in the organ homogenate may ob- 
scure the assay. Homogenization was therefore done at 4~  and 
in a volume diluting neutralizing antibody to below the limit of 
detection in the plaque reduction assay (see below). 
Assay  for Neutralizing Serum Antibody.  The titer of neutralizing 
antibody in sera from latently infected mice was determined from 
the half-maximal plaque reduction in a conventional plaque reduc- 
tion assay. 103 PFU of purified murine CMV in 0.1 ml of plaque 
assay medium (14) were incubated at 37~  for 2 h in standard vials 
(Eppendorf, Hamburg, Germany) with 0.1 ml of native serum (or 
organ homogenate; see above) in appropriate dilutions, followed 
by the virus plaque assay. 
Immunoprecipitation of CMV Proteins.  As a source of viral an- 
tigens, lysates of infected MEF were prepared 24 h after infection 
after a 4-h period of metabolic labeling with [3SS]methionine in 
the late phase of viral gene expression. Lysates from CV-1 cells were 
made 7 h after infection with vaccinia virus wild-type strain Copen- 
hagen  or  with  the  vaccinia  virus  recombinant  Vac-gB  which 
expresses the gB gene of murine CMV (15). Procedures for biosyn- 
thetical labeling,  preparation of cell lysates, and the immunopre- 
cipitation as well as the protein separation on SDS-polyacrylamide 
(7.5%) gels were done as described  previously (15, 16). 
Detection of Viral and Cellular DNA.  Organs from latently in- 
fected mice and blood leukocytes from acutely infected mice were 
processed for DNA isolation, and specific viral and cellular DNA 
sequences were amplified by employing PCR based on published 
methods (17) with certain modifications (12). In brief, a 363-nucleo- 
tide sequence  was  amplified  from exon 4  of the murine CMV 
immediate-early (IE) gene iel (18) by using oligonudeotides IE1.1983 
and IE1.2345 as forward and reverse primer, respectively, and oli- 
gonucleotide IE1.2135 as the probe for the verification of the iden- 
tity of the amplification  product (12). Primers and probe for de- 
tecting the/~-actin gene as a cellular gene control have been specifed 
previously (12). Throughout, 3-#g samples of DNA were subjected 
to 35 cycles of amplification.  In the titration of blood leukocytes, 
the leukocyte DNA  was  supplemented  to 3 #g with certified- 
negative carrier DNA. The amplification  products were analyzed 
by electrophoresis on 1.4% agarose minigels,  Southern blotting, 
hybridization with the respective 32p-endlabeled probe, and auto- 
radiography. 
Samples with all components except template DNA provided 
the technical negative control. The 12.2 kbp plasmid piE111, which 
encompasses  genes iel and ie3 of murine CMV, served as positive 
controls. The assay sensitivity was determined by titrating 1-1,000 
molecules of plasmid piE111 to 3 #g of carrier DNA from organs 
of uninfected mice. It was found that 10 copies of the viral gene 
can generally be detected, that the signal intensities usually increase 
linearly'between 10 and 100 copies, and that the sensitivity of de- 
tection is not influenced by the organ source of the carrier DNA 
(12). Therefore, 10 and 100 molecules  of piE111 mixed to 3/zg 
of certified-negative spleen DNA were included in the PCR ex- 
periments as positive controls. The PCR was evaluated semiquan- 
titatively by ranking the signals as <10, 10, 100, and >100 copies 
of the viral test sequence. 
Results 
The Course of  Primary Infection Differs with the Infection His- 
tory.  Human  CMV  is  frequently acquired  perinatally  or 
during early childhood, and a second epidemiologic wave of 
primary infection is based on sexual transmission  between 
adults.  For  both  epidemiologic  groups,  seropositivity for 
CMV-specific antibodies is indicative of prior infection, and 
the serological status currently serves as the only criterion 
for predicting a risk of CMV recurrence in transplantations 
(8). It is so far unknown whether the history of primary in- 
fection leads to differential risks of recurrence within the risk 
group of seropositives.  We have compared the infection of 
neonates and that  of adults in the murine model of CMV 
infection to investigate the influence of primary infection on 
the establishment  of latency and  the risk of recurrence. 
The experimental regimen and  the  time schedule along 
which acute/persistent primary infection develops into latent 
infection are schematically outlined in Fig.  1. One group of 
BALB/c mice, referred to as experimental group N, was in- 
fected intraperitoneally  with  10 2 PFU  of purified  murine 
CMV as neonates on the first day after birth,  whereas  the 
second group, referred to as experimental group A, was in- 
fected subcutaneously  as young adults  at  the age of 2  mo 
with  10 5 PFU in  the left hind footpad.  Duration,  extent, 
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Figure  1.  Experimental  regimen  and time schedule  for establishment 
of latency  and induction  of recurrence. (Group N) Mice infected  as neo- 
nates. (Group  A) Mice infected  as adults. (Black cones) Symbolize  duration 
and productivity  of virus replication  in salivary  glands during  persistence 
and recurrence. 
and organ sites of acute virus multiplication differed markedly 
between these two groups (Fig.  2).  In the neonates, CMV 
caused disease with ,,040% mortality occurring typically in 
the third week. During the period of mortality, high virus 
titers were observed in a number of organs. Survivors showed 
a runting diseaselike  growth retardation until ,,o4-6  wk. 
Around that time, virus multiplication ceased in most tissues 
except in the salivary glands, where a persistent virus replica- 
tion continued until 4-6 mo. Beyond 6 mo, the infection 
had become latent in most individuals with viral DNA de- 
tectable by PCR in organs as well as in blood leukocytes (12). 
In contrast, in adult mice, the infection did not cause mor- 
tality or significant morbidity. Virus replication above the 
detection level was observed only in the salivary glands, and 
discontinued at this privileged site ~2 mo after infection (Fig. 
2). These findings are in good agreement with previous  ex- 
perience (9,  14). In summary, in both models, the salivary 
glands represent the organ site of persistence,  but in group 
N  the acute infection is disseminated, the duration of the 
persistent phase is longer, and the overall virus productivity 
is much higher than in group A. We therefore asked next 
whether these marked differences in primary infection are 
reflected by differences in the amount of viral genome har- 
bored in organs during latency. 
The History of Primary Infection  Determines the Tissue Load 
of Latent CMV.  We have shown in previous work that in 
infected neonates, viral DNA is maintained in blood leuko- 
cytes for up to 6 mo after resolution of productive infection, 
but is then cleared to below the limit of detection by PCK. 
At that stage of latency,  viral DNA remained prevalent  in 
organs, and, in comparison with the spleen, the lungs then 
proved a major organ site of CMV latency and recurrence 
(12). We therefore concentrated on the lungs to compare tissue 
loads of latent viral DNA in experimental groups N  and A 
1 yr after infection (Fig.  3).  To exclude cases of persistent 
infection or of spontaneous recurrence,  the six individuals 
shown for each group were pretested for absence of infec- 
tious virus in tissue fragments from salivary glands, lungs, 
and spleen.  In addition, it was assured  for each individual 
that the viral test sequence, a 363-nucleotide sequence from 
exon 4 of the IE gene iel  (12), was no longer detectable in 
blood leukocytes by PCR (data  not shown).  In group N, 
viral DNA was detected in the lungs of all six mice with 
uniformly high copy numbers of >100 in 3/zg samples of 
organ DNA,  which equals  >200 copies  in  106 tissue cells 
(Fig.  3,  top).  In contrast, in group A, the test sample was 
negative for two out of six mice tested, and in the four posi- 
tive cases, the copy numbers of the viral sequence were <10 
(Fig. 3, bottom). A sequence from murine B-actin was amplified 
in both groups with indistinguishable efficacy from 30 ng 
samples  of lung DNA (Fig.  3). 
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Figure 2.  Course  of primary  murine  CMV infection.  Mice 
were infected as indicated in Fig. 1 as neonates (group N) 
or as adults (group  A). Survival  rate (n = 20) and virus titers 
in organs  were  monitored.  Symbols  represent three  mice  tested 
individually.  (Vertical  bar) Range; (horizontal  bar) median  value. 
(DL) Detection limit of the virus plaque assay. Figure  3.  Prevalence  of latent viral  DNA in the lungs. A 363-nucleotide 
sequence of exon 4 of the murine CMV immediate-early  gene ieI was 
amplified by PCK from 3/~g samples of lung DNA of six individual, 
latently infected  mice (test lanes I-6) of experimental  groups N and A 
1 yr after inoculation, that is, at a time when viral DNA was no longer 
detectable by PCR in blood. As a control for the technical efficacy  of 
amplification, a sequence  from  the cellular  mouse/~-actin  gene  was amplified 
from 30 ng of the same lung DNA samples. (Lane  ~b) All reagents except 
DNA; (control  lanes I and 2) 10 and 100 copies, respectively,  of plasmid 
piE111 mixed to 3/~g of certified-negative  carrier  DNA derived  from the 
spleen of an uninfected mouse. 
This difference was not unique to the lungs. For a repre- 
sentative animal of either group (Figs.  4 and 5 correspond 
to individuals N2 and A2), the load of latent viral DNA is 
shown in greater detail by a screening of several organs on 
the basis of six independently amplified samples  per organ. 
In individual N2, all organs tested were clearly positive, al- 
though with marked differences between organs. The overall 
load was much lower in individual A2.  Specifically,  spleen 
Figure 4.  Organ  distribution of  latent viral  DNA after  neonatal  infec- 
tion. The viral  363-nucleotide  test sequence  was amplified  from  organ  DNA 
of the individual mouse  N2. Control lanes as in Fig. 3. (Lanes  a-f) Six 
independently amplified 3-/zg samples of organ DNA. 
Figure  5.  Organ  distribution  of  latent  viral  DNA after  infection  at adult 
age. Legend as for Fig. 4, except  that individual A2 was tested. 
and kidney were negative at this assay sensitivity, and sali- 
vary glands, adrenal glands, and heart were subject to sam- 
pling variance with only one of six samples  positive, con- 
taining  <10  copies.  However,  the  viral  genome  was  not 
cleared from this individual, as the lungs contained "~10 copies 
of the viral sequence in all six samples  tested, which corre- 
sponds to "~20 copies per 106 tissue cells. Thus,  the lungs 
represent a preferred organ site of murine CMV latency not 
only after neonatal infection (12), but also after infection of 
adults. The overall impression from Figs. 3-5 is that the organ 
distribution of latent viral DNA is qualitatively similar for 
both protocols of CMV latency, whereas the absolute tissue 
load is significantly higher in neonataUy infected mice. 
Segregation Between Acute Productivity and Load of  Latent Ge- 
nome.  Whereas the data have indicated that virus dissemi- 
nation during primary infection is important for a wide organ 
distribution of the latent viral genome, there is no absolute 
correlation between the productivity during primary acute/ 
persistent infection and the amount of latent viral genome 
in a particular organ. The salivary glands represented the site 
of virus persistence in both groups of latently infected mice. 
However, the high and long-lasting virus productivity in the 
salivary  glands is not quantitatively reflected by an accord- 
ingly high load of latent viral DNA (Figs.  4 and 5). This 
is particularly obvious in latently infected adults (Fig.  5, in- 
dividual A2;  Fig.  6, individuals A1  and A3), in which the 
lungs consistently harbored more latent genome than did the 
salivary glands,  even though virus replication during primary 
infection was barely detectable in the lungs  (see Fig.  2). 
The Risk of  Recurrence Correlates with the Tissue Load of  La- 
tent CMV.  The amplification of a viral DNA sequence from 
host tissues by PCR does not discriminate between defective 
and functional genomes. The proportion of functional latent 
genomes capable of initiating recurrent infection may differ 
between organs. We therefore induced recurrence in vivo (12) 
to test whether the amount of viral DNA detected by PCK 
can be used as a predictor for the risk of recurrence (Table 
1). The experiment was done I yr after infection, when in- 
188  Risk of Cytomegalovirus  Recurrence from Latency Figure 6.  Comparison of latent CMV load in salivary  glands and lungs 
after infection at adult age. Legend as for Fig. 4, except that individuals 
A1 and A3 were tested. 
fectious virus was no longer detectable in any organ  (n  = 
30; 0/30 positive). The incidence of induced recurrence was 
compared for experimental groups N  and A, and was moni- 
tored for three organs separately. A negative score was given, 
if no virus was detected. Titers for positive scores ranged from 
102 to  104 PFU. 
In organs  of mice infected as adults,  recurrent virus was 
not  detectable,  except in  the lungs  of two  individuals  out 
of 30 tested (Table 1, group A). In contrast, there was a highly 
significant recurrence in mice infected as newborns (Table 1, 
group N). Interestingly, recurrent virus was rarely found simul- 
taneously in all three organs tested. Instead, discrete patterns 
of virus distribution were observed (Table 1, patterns II-VIII). 
The cumulative incidence of recurrence in the three organs 
tested was  63%  in  this  experiment,  whereas  the incidence 
for any particular organ was lower (summing up of patterns 
II-VIII). As a consequence, screening of only one organ for 
recurrent CMV underestimates the overall incidence of recur- 
rence, and,  accordingly, the determined incidence is only a 
minimum estimate, as possible recurrence in further organs 
remained untested. The organ-specific incidence was high for 
salivary glands  and lungs,  and lower for the spleen.  Thus, 
overall and organ-specific incidences  of recurrence reflected 
the respective differences in the amount  of viral DNA  de- 
tected by PCP,. 
Evidence for Stochastic Multifocal  Recurrence.  The demon- 
stration of latent viral DNA in multiple organs and the ob- 
served discrete patterns of recurrence with more frequent de- 
tection of recurrent virus in those organs that harbored latent 
CMV in high copy number,  strongly suggested that recur- 
rence is a'stochastic event that occurs independently in different 
organs with a likelihood defined by the number of latent viral 
genomes in tissue.  The alternative would be that recurrent 
CMV originates from a single site of latency and disseminates 
to multiple organs where it may be detected with different 
sensitivity based on differential productivity of the tissue cells. 
As the salivary glands represent the privileged site of CMV 
replication,  cases of positive  salivary  glands  corresponding 
to negative lungs and  spleen (Table 1,  pattern  II) are not a 
strong argument against dissemination.  However, along the 
same line of argument,  the frequent cases of positive lungs 
corresponding to negative salivary glands  (Table 1,  pattern 
III) are not compatible with dissemination.  If recurrence is 
a stochastic multifocal event, cases of coincident recurrence 
in two or more organs must occur with an incidence predicted 
by the laws of statistics.  This is indeed the case for the data 
in Table  1.  When  tested by Fisher's  exact probability  test, 
the number of observed double-positive events for all three 
possible pairs between three organs is in good agreement with 
the hypothesis of independent distribution (p-values ranging 
from 0.25  to 0.55). 
Neutralizing Antibody Does Not Prevent Recurrence  Antiviral 
antibody must be discussed as an additional parameter that 
Table  1.  Incidences  of Induced Murine CMV Recurrence 
Detection of recurrent CMV  in  organs 
Pattern  Salivary  glands  Lungs  Spleen  Incidence group N  Incidence group A 
I  -  -  -  11/30  28/30 
II  +  -  -  5/30  0/30 
III  -  +  -  6/30  2/30 
IV  -  -  +  2/30  0/30 
V  +  +  -  3/30  0/30 
VI  +  -  +  2/30  0/30 
VII  -  +  +  0/30  0/30 
VIII  +  +  +  1/30  0/30 
II-VIII  group N  11/30  (36.7%)  10/30  (33.3%)  5/30 (16.7%)  19/30  (63.3%) 
II-VIII  group A  0/30  2/30 (6.7%)  0/30  2/30  (6.7%) 
CMV recurrence was induced by 6 Gy of 3,-irradiation in groups of 30 latently infected BALB/c mice inoculated as newborns (group N) or as adults 
(group A). Virus was detected by plaque assay at day 14 after the irradiation. 
189  P.eddehase  et al. Figure  7.  Antiviral specificity and virus neutralization  capacity of im- 
mune sera. Serum was pooled from five mice each of experimental groups 
N and A shortly before the recurrence experiment  (see Table 1). (a) (Left) 
Immunoprecipitation  of viral late-phase proteins.  (Lane 1) Nonimmune 
serum tested with lysate from infected MEF; (lanes 2 and 3) sera of groups 
N and A, respectively, tested with lysate from uninfected MEF; (lanes 4 
and 5) two independent  immunoprecipitations  from infected MEF with 
group N serum; (lanes 6 and 7) with group A serum, accordingly. (Right) 
Immunoprecipitation of the murine CMV glycoprotein  B (gB). (Lane 8) 
Immunoprecipitation with group A serum from lysate of CV-1 cells in- 
fected with wild-type vaccinia virus, strain Copenhagen;  (Lanes 9 and 10) 
immunoprecipitation with group N and group A serum, respectively, from 
lysate of CV-1 cells infected with the recombinant  vaccinia virus Vac-gB. 
(b) Plaque reduction  assay determining  the titer of virus neutralizing  anti- 
bodies in group N (I) and group A (O) sera. Serum pooled from unin- 
fected, age-matched mice served for control (O). Counted plaque numbers 
are normalized. 
Figure 8.  Reduction of hematogenic  virus dissemination by immune 
serum.  (a) Virus titers were determined in organs of 3,-irradiated (6 Gy), 
bone marrow reconstituted  BALB/c recipients 2 wk after s.c. infection 
(105 PFU).  The day before infection,  the mice were passively immunized 
by i.v. transfer of 0.1 or 0.5 (*) ml of serum derived from primed B6 mice 
(CMV/B6) or from primed B  cell-deficient  tzMT//.tMT  mutant  mice 
(CMV/#MT). Groups with no serum transfer (No) or transfer of serum 
from unprimed B6 mice (B6) served as negative controls. Symbols repre- 
sent five individual mice per group.  The median values are marked by a 
horizontal  bar. (b) Frequency of blood leukocytes carrying viral DNA. 
1 mo after serum transfer (0.5 ml) and infection,  the viral 363-nucleotide 
test sequence was detected by PCR in graded numbers of leukocytes. (Lane 
~) No template DNA; (control lanes 1 and 2) 10 and 100 copies, respec- 
tively, of plasmid piE111 supplemented to 3/lg with carrier DNA; (test 
lanes 0-6) DNA from  100 to  106 blood leukocytes,  respectively, sup- 
plemented  to 3/~g with carrier DNA at cell numbers  of <106. 
may influence the risk of recurrence and account for the differ- 
ence between adult and neonatally latent mice. We have there- 
fore determined  the serological  status  for both  groups  (Fig. 
7), qualitatively by immunoprecipitation  of viral proteins (Fig. 
7 a) and quantitatively by the functional test of virus neutral- 
ization  (Fig.  7  b).  There  were differences  in  the capacity of 
both  sera for precipitating  viral proteins  from lysates  of in- 
fected  MEF,  with  group  A  serum  precipitating  more pro- 
teins (Fig. 7 a, left).  However, serum from neonatally infected 
mice was equally potent  in precipitating  the  130-kD  glyco- 
protein B  (gB) of murine CMV  (15) from lysates of cells in- 
fected  with  the  recombinant  vaccinia  virus  Vac-gB  (Fig.  7 
a,  right). This  finding  is  relevant,  as  the  human  homolog, 
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tion by neutralizing  antibodies (19),  and vaccination with 
Vac-gB protects mice against lethal challenge infection (Rapp, 
M.,  and  U.  H.  Koszinowski,  manuscript  in preparation). 
Moreover, the serum of group N  proved to have a fourfold 
higher  titer  of neutralizing  antibody (Fig.  7 b).  Thus,  the 
incidence of induced recurrence was higher in organs of neo- 
natally infected mice in spite of a higher titer of neutralizing 
antibodies in  serum. 
Evidence that Serum Antibody  Controls Virus Dissemination. 
The finding that recurrent infection led to discrete patterns 
of positive organs  (see Table 1) requires an explanation.  If 
y-irradiated (6 Gy), unprimed mice are infected intravenously, 
1-2 PFU are sufficient to cause disseminated infection in all 
susceptible organs. In contrast, latently infected mice are resis- 
tant  against i.v.  superinfection with ~105 PFU even when 
cellular immunity by CD8 T  cells is abrogated by in vivo 
anti-CD8 treatment in addition to the y-irradiation (data not 
shown). These observations, along with the known protec- 
tive antiviral capacity of passive immunization with immune 
serum (20),  suggest  that  antiviral  antibody was the factor 
that prevented the dissemination of recurrent infection from 
the organ sites of recurrence to unaffected organs in the ex- 
periment  of Table 1. 
To exclude an involvement of putative other immune serum 
components, serum from CMV-primed B cell-deficient/zMT 
mutant  mice (13) was compared with  serum from primed 
parental  B6 mice with  respect  to  the  efficacy  in blocking 
hematogenic dissemination of CMV upon prophylactic i.v. 
transfer into  nonimmune  recipient  mice (Fig.  8).  The day 
after the serum transfer,  the recipients were "y-irradiated, bone 
marrow reconstituted, and infected subcutaneously with mu- 
rine CMV. The bone marrow transplantation  was required 
to overcome the lethal bone marrow aplasia and blood pan- 
leukopenia caused by CMV (21). Antibody-containing serum 
from parental B6, but not antibody-free serum from the/xMT 
mutant,  reduced  virus  titers  in  target  organs  in  a  dose- 
dependent manner (Fig. 8 a). Moreover, the frequency of blood 
cells that carried viral DNA detected by PCR 1 mo after in- 
fection  was  reduced  from  1/10  to  1/104  by  parental  B6 
serum (Fig.  8 b). In conclusion, antiviral antibody can limit 
hematogenic  dissemination  of CMV. 
Discussion 
For clinical CMV in transplantations,  a potential risk of 
recurrence is defined qualitatively by the  serological status 
of transplantation donor and recipient (8). However, CMV- 
specific antibody is only indicative of latent CMV infection, 
and the low positive predictive value of seropositivity for re- 
current CMV infection and disease does not justify prophy- 
lactic antiviral treatment. Primary CMV infection can occur 
throughout life, and is usually not diagnosed, because it passes 
without overt symptoms. Thus, except in rare cases of a clin- 
ical CMV  anamnesis,  the time point  of primary infection 
is unknown for the individual patient,  and seropositives are 
viewed in case statistics as a uniform risk group. It is there- 
fore open to question, whether the individual risk differs with 
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the history of primary infection, and which parameters could 
be used as more reliable predictors for the risk of recurrence. 
In this paper, we have compared the risks ofmurine CMV 
recurrence in experimental models designed to represent two 
more distant cases in the infection epidemiology of human 
CMV, namely the infection of neonates and adults. The data 
have shown that the risk of recurrence differs largely between 
the two groups. Neonatal infection is associated with a high 
risk of recurrence, whereas the risk is low when primary in- 
fection occurred at  adult  age. 
Specifically, four major conclusions can be drawn from the 
experiments: (a) the extent of virus replication and dissemi- 
nation  during  primary  infection,  which is high  after neo- 
natal infection and low after infection of adults, determines 
the overall burden of latent viral DNA in organs; (b) the copy 
number of latent viral DNA in organs correlates with the 
overall and organ-specific incidences of in vivo recurrence; 
(c) recurrence is a stochastic, focal event that occurs indepen- 
dently in different organs; and (d) antiviral antibody cannot 
preclude recurrence at the organ sites of latency, but can limit 
virus dissemination. 
In their inquiry into the mechanisms ofc~- and 'y-herpesvirus 
latency, Roizman and Sears (4) proposed a determinative role 
of primary infection, and specifically,  an importance of the 
copy number of latent  viral genome for recurrence.  These 
principles are now demonstrated for a ~-herpesvirus.  CMV 
latency differs from herpes simplex virus latency by its wide 
organ distribution. The presence of latent CMV in multiple 
organs provides the molecular basis for recurrence from mul- 
tiple organs. A cellular site of CMV latency has not yet been 
precisely identified. For murine CMV latency in the spleen, 
there is evidence for a location of latent viral DNA in the 
stromal compartment (22, 23), and the sinusoidal lining cell 
is discussed as a candidate (22). The low frequency oflatently 
infected cells revealed  by PCR. (12) has  so far precluded an 
analysis of the affected cell type in other organs. It is a prom- 
ising aspect of our results that knowledge of the latently in- 
fected cell and of the viral copy number per cell is not a pre- 
requisite for predicting the risk of recurrence, as the average 
viral copy number relative to tissue DNA, estimated from 
PCR amplification of a single essential viral gene, can substi- 
tute for that  information.  This may be of practical impor- 
tance with respect to a possible prognostic medical applica- 
tion. According to our findings,  a high copy density in a tissue 
predicts a low threshold for recurrence. It should be possible 
to test that prediction at least for the donor organ-associated 
risk in transplantation  patients. 
At first glance, the finding that the viral copy number in 
latently infected salivary gland tissue does not quantitatively 
reflect the gross productivity during acute and persistent in- 
fection argues against the proposed role for viral replication 
in the establishment  of latency.  A  discrepancy was particu- 
larly obvious in mice infected as adults, in which latent viral 
genome was barely detectable in salivary glands,  even though 
virus had been replicating  there in the persistent phase for 
several weeks. There is an explanation for this finding. During 
persistent infection in the salivary  glands,  virus replication 
is confined to a particular cell type, the acinar  glandular epi- thelial cell (24, 25). As termination of persistence is associated 
with necrosis of this producer cell (24), another cell type must 
be proposed as the cellular site of latency. 
The observation of stochastic recurrence in various organs 
(Table 1) may help to explain another unsolved problem in 
the prediction of CMV disease. Interstitial pneumonia is the 
most  frequent manifestation of human  CMV  after bone 
marrow transplantation (26,  27),  but,  on occasion, other 
manifestations predominate and range from specific organ dis- 
eases to multiorgan disease. We predict from our results in 
the experimental model  that patients with a high overall 
burden of latent CMV are at risk of a multifocal recurrence 
in many organs, which can resemble disseminated CMV dis- 
ease after primary infection of an immunocompromised host. 
In contrast, in patients in which the overall burden of latent 
CMV is low, recurrence is more likely to occur only in single 
organs, with a preference for organs with high copy numbers 
of latent viral DNA. If, for instance,  recurrence takes place 
by chance in the lungs, interstitial pneumonia can be the re- 
sult, whereas recurrence in salivary glands leads to virus secre- 
tion without overt  CMV disease. 
There is considerable  interest in antibody prophylaxis of 
posttransplant CMV disease as well as in vaccination trials 
(28).  However, from the clinical experience,  the benefit of 
such approaches is controversial (29). That antiviral antibodies 
do not preclude recurrence has always been obvious from the 
epidemiologic data, according to which seropositivity was 
even used as a qualitative risk predictor. The model has re- 
produced this, but it proposes  a beneficial role for antibody 
in the prevention of disseminated infection after a focal re- 
currence. 
In essence, the concept of  multifocal cytomegalovirus latency 
and recurrence provides  a rationale for the as yet poorly un- 
derstood diversity in the disease manifestations of CMV. In 
may prove  useful as a basis  for further studies. 
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